Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.

Read More »

Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged

Read More »

Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9

Read More »

Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.

Read More »

Cellect Biotechnology Ltd.: Exposure to the global stem cells industry

Read More »